Effect of <scp>HIPEC</scp> according to <scp>HRD</scp> / <scp> <i>BRCA</i> wt </scp> genomic profile in stage <scp>III</scp> ovarian cancer: Results from the phase <scp>III OVHIPEC</scp> trial-Reference-Cited by-同舟云学术

Effect of HIPEC according to HRD / BRCA wt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial

Published:2022-06-04 Issue:8 Volume:151 Page:1394-1404
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Koole Simone N.¹²^ORCID,Schouten Philip C.³,Hauke Jan⁴^ORCID,Kluin Roel J. C.⁵,Nederlof Petra⁶,Richters Lisa K.⁴,Krebsbach Gabriele⁴,Sikorska Karolina⁷,Alkemade Maartje⁸,Opdam Mark⁸,Schagen van Leeuwen Jules H.⁹,Schreuder Henk W. R.¹⁰,Hermans Ralph H. M.¹¹,de Hingh Ignace H. J. T.¹²,Mom Constantijne H.¹³,Arts Henriette J. G.¹⁴,van Ham Maaike¹⁵,van Dam Peter¹⁶,Vuylsteke Peter¹⁷¹⁸,Sanders Joyce⁶,Horlings Hugo M.⁶,van de Vijver Koen K.¹⁹,Hahnen Eric⁴^ORCID,van Driel Willemien J.¹,Schmutzler Rita⁴,Sonke Gabe S.²,Linn Sabine C.²^ORCID

Affiliation:

1. Department of Gynecology, The Netherlands Cancer Institute Center of Gynecologic Oncology Amsterdam Amsterdam The Netherlands

2. Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

3. Department of Molecular Pathology The Netherlands Cancer Institute Amsterdam The Netherlands

4. Faculty of Medicine and Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Cologne University Hospital Cologne Cologne Germany

5. Genomics Core Facility Netherlands Cancer Institute Amsterdam The Netherlands

6. Department of Pathology The Netherlands Cancer Institute Amsterdam The Netherlands

7. Department of Biometrics The Netherlands Cancer Institute Amsterdam The Netherlands

8. Core Facility of Molecular Pathology and Biobanking The Netherlands Cancer Institute Amsterdam The Netherlands

9. Department of Obstetrics & Gynecology Sint Antonius Hospital Nieuwegein The Netherlands

10. Department of Gynecological Oncology University Medical Center Utrecht Utrecht The Netherlands

11. Department of Gynecology and Obstetrics Catharina Hospital Eindhoven The Netherlands

12. Department of Surgical Oncology Catharina Hospital Eindhoven The Netherlands

13. Department of Obstetrics and Gynecology Amsterdam University Medical Center, Center of Gynecologic Oncology Amsterdam Amsterdam The Netherlands

14. Department of Gynecological Oncology University Medical Center Groningen Groningen The Netherlands

15. Department of Gynecological Oncology Radboud University Medical Center Nijmegen The Netherlands

16. Department of Gynecologic Oncology University Hospital Antwerp Antwerp Belgium

17. Department of Medical Oncology UCL Louvain, CHU Namur Sainte‐Elisabeth Namur Belgium

18. University of Botswana Gaborone Botswana

19. Department of Pathology University Hospital Ghent Ghent Belgium

Funder

Korea National Institute of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34124

Reference32 articles.

1. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer

2. Carcinoma of the Ovary

3. Ovarian cancer statistics, 2018

4. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

5. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer;Critical Reviews in Oncology/Hematology;2024-10

2. Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1);British Journal of Cancer;2024-06-12

3. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04

4. Discrepancy between recommendations regarding hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer management: a narrative review;Chinese Clinical Oncology;2024-06

5. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations;JAMA Network Open;2024-04-09